Publications by authors named "David Warnock"

Claim this Profile
A
A modified Delphi consensus on periprosthetic infection in orthopaedic oncology : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).
Lee Jeys, Eduardo Botello, Richard A Boyle, Walid Ebeid, Matthew T Houdek, David Warnock

Bone Joint J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is debridement, antibiotics, and implant retention in orthopaedic oncology? : a global cross-sectional survey of surgeons' practices and opinions.
Zeeshan Khan, Zainab Aqeel Khan, Tomas Zamora, Ashish Gulia, Santiago A Lozano-Calderon, David Warnock

Bone Jt Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in Understanding the Pathophysiology of Fabry Disease.
David G Warnock, Aleš Linhart, Anthony J Bleyer, Stanislav Kmoch

Nephron· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded View of the Pathophysiology of Fabry Disease.
Stanislav Kmoch, Martina Živná, Moran Dvela-Levitt, Fabian Braun, Paula Rozenfeld, David G Warnock

Nephron· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying consensus and areas for future research in chondrosarcoma : a report from the Birmingham Orthopaedic Oncology Meeting.
Lee M Jeys, Guy V Morris, Vineet J Kurisunkal, Eduardo Botello, Richard A Boyle, David Warnock

Bone Joint J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Myrl Holida, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens, David G Warnock

J Inherit Metab Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brenner's Unforgettable Legacy: Transforming Medicine and Renal Science for Generations.
Giuseppe Remuzzi, David Warnock

Nephron· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Eric L Wallace, Ozlem Goker-Alpan, William R Wilcox, Myrl Holida, John Bernat, David G Warnock

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
David G Warnock, Eric L Wallace

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in orthopaedic oncology.
Lee M Jeys, Joachim Thorkildsen, Vineet Kurisunkal, Ajay Puri, Pietro Ruggieri, David Warnock

Bone Joint J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study.
Katharine L Cheung, Deidra C Crews, Mary Cushman, Ya Yuan, Katherine Wilkinson, David G Warnock

Am J Kidney Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease.
Valeria Nikolaenko, David G Warnock, Kevin Mills, Wendy E Heywood

Hum Mol Genet· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.
Christoph Wanner, Virginia Kimonis, Juan Politei, David G Warnock, Nurcan Üçeyler

Mol Genet Metab Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities in 2022.
David G Warnock

Nephron· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
Albina Nowak, Felix Beuschlein, Visnuka Sivasubramaniam, David Kasper, David G Warnock

J Med Genet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury.
David G Warnock, Javier A Neyra, Etienne Macedo, Ayme D Miles, Ravindra L Mehta

Nephron· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm.
John L Jefferies, Alison K Spencer, Heather A Lau, Matthew W Nelson, Joseph D Giuliano, David G Warnock

Orphanet J Rare Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative.
Derralynn A Hughes, Patricio Aguiar, Patrick B Deegan, Fatih Ezgu, Andrea Frustaci, David G Warnock

BMJ Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a rare disease registry for establishing phenotypic classification of previously unassigned variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup.
Dominique P Germain, João Paulo Oliveira, Daniel G Bichet, Han-Wook Yoo, Robert J Hopkin, David G Warnock

J Med Genet· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Dana V Rizk, Arnold L Silva, Pablo E Pergola, Robert Toto, David G Warnock

Cardiorenal Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trials during the SARS-CoV-2 Pandemic.
David G Warnock

Nephron· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Investigational Therapeutics for Fabry Disease.
Andrew Felis, Michael Whitlow, Abigayle Kraus, David G Warnock, Eric Wallace

Kidney Int Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease.
Ivan D Doykov, Wendy E Heywood, Valeria Nikolaenko, Justyna Śpiewak, Jenny Hällqvist, David G Warnock

J Med Genet· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Peter Rossing, Geoffrey A Block, Melanie P Chin, Angie Goldsberry, Hiddo J L Heerspink, David G Warnock

Kidney Int· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary Oxidative Balance Scores and Biomarkers of Inflammation among Individuals with and without Chronic Kidney Disease.
Kristin J Marks, Terryl J Hartman, Suzanne E Judd, Titilayo O Ilori, Katharine L Cheung, David G Warnock

Nephron Extra· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis